The fact that overall efficacy was almost identical between the combination and Eylea only treatment arms does suggest that they were comparable groups as a whole. It might suggest then that any other differences identified are more likely to be real trends even if they don't reach statistical significance because of the sample size.
Ann: Opthea Reports Positive Ph2a Trial Results of OPT-302 in DME, page-61
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
81.5¢ |
Change
0.030(3.82%) |
Mkt cap ! $1.003B | |||
| Open | High | Low | Value | Volume |
| 78.5¢ | 82.5¢ | 78.5¢ | $1.203M | 1.499M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5772 | 81.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 82.5¢ | 844 | 1 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| OPT (ASX) Chart |